A Phase 3 interventional study of somatropin in Growth Hormone Disorder, Growth Hormone Deficiency in Children and Genetic Disorder, sponsored by Novo Nordisk A/S. Completed at 6 sites in Israel. Per ClinicalTrials.gov, last updated 2017-02-27.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Human Growth Hormone in Turner Syndrome — none open to participants now, none under way, none of them phase 3. Human Growth Hormone · Turner Syndrome.
Among the 14 studies testing Human Growth Hormone in Turner Syndrome, this one is the 3rd largest by enrollment, is the only one that started in 2000, is one of 6 in phase 3, and was the 12th registered.
125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.
Browse Turner Syndrome studies →None of the 14 studies testing Human Growth Hormone in Turner Syndrome is open now. The open studies under Turner Syndrome, anywhere →
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 25 Turner Syndrome studies recruiting now, 8 (32%) set no upper age limit and 14 (56%) stop at 75 or younger; 15 take children under 18; 5 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1987; this study’s year is marked. 1 started in 2000.
This study's enrollment of 168 is above the median of 67 across 52 interventional studies indexed under Turner Syndrome.
Median enrollment 108 across the 14 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 8 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
12 studies in Turner Syndrome by Novo Nordisk A/S: none open now, 2 under way, 2 of them phase 3. Of 10 finished, 1 (10%) have results posted.
Among the 12 studies in Turner Syndrome by Novo Nordisk A/S, this one is the only one that started in 2000, is one of 5 in phase 3, and was the 7th registered.
Novo Nordisk A/S’s Turner Syndrome studies by the year they started, since 1987.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing Human Growth Hormone in Turner Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 12 in Turner Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this trial is to evaluate the new liquid somatropin formulation in children with growth hormone deficiency.
125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.
This study's enrollment of 168 is above the median of 67 across 52 interventional studies indexed under Turner Syndrome.
Browse Turner Syndrome studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Turner Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Genetic Diseases, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: somatropin
Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
Patient acceptance of the new liquid growth hormone formulation
Number of Adverse Events (AE)
Number of Serious Adverse Events (SAE)
Ran from Oct 2000 to primary completion in Oct 2002, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone